1190391-40-2

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 441285-17-2 (3-{[(benzyloxy)carbonyl]amino}phenyl)acetic acid 
• 501-53-1 benzyl chloroformate 
• 1190391-39-9 ethyl (3-{[(benzyloxy)carbonyl]amino}phenyl)acetate 
• 52273-79-7 (3-amino-phenyl)-acetic acid ethyl ester 

Downstream Products

• 1190391-55-9 benzyl {4-[(3E,5R,6R)-5-{[(benzyloxy)carbonyl]amino}-6-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-chlorophenyl)-2-oxohex-3-en-1-yl]phenyl}carbamate 

Relevant academic research and scientific papers

NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.